Evidence map›Paper›PMID 41807133›Full record

ArticleInternational journal of stem cells2026

Exploring the Potential of Wharton's Jelly-Derived Mesenchymal Stem Cells as a Therapeutic Approach for Preterm Premature Rupture of Membranes.

Hyeongseop Kim, Hyunju Kim, Suyeon Jeon, Soo-Young Oh, Sang Eon Park, Hong Bae Jeon, Jung-Sun Kim, Suk-Joo Choi, Jong Wook Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of stem cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hyeongseop KimNew Drug Development Division, ENCell Co., Ltd., Seoul, Korea.ORCID https://orcid.org/0000-0001-8546-6472
Hyunju KimNew Drug Development Division, ENCell Co., Ltd., Seoul, Korea.ORCID https://orcid.org/0009-0008-9485-2891
Suyeon JeonNew Drug Development Division, ENCell Co., Ltd., Seoul, Korea.ORCID https://orcid.org/0009-0008-2622-6792
Soo-Young OhDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3002-0048
Sang Eon ParkNew Drug Development Division, ENCell Co., Ltd., Seoul, Korea.ORCID https://orcid.org/0009-0000-2609-2095
Hong Bae JeonNew Drug Development Division, ENCell Co., Ltd., Seoul, Korea.ORCID https://orcid.org/0000-0003-4420-9968
Jung-Sun KimDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7221-2737
Suk-Joo ChoiDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8946-4789
Jong Wook ChangCell & Gene Therapy Institute, Samsung Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0001-9335-5510

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preterm premature rupture of membranes (PPROM) is a major cause of preterm birth and neonatal morbidity, with no established treatment to restore membrane integrity. Mesenchymal stem cells (MSCs), known for their regenerative and immunomodulatory properties, harbor promising therapeutic potential for fetal membranes repair. This study aimed to evaluate the rapid barrier reinforcement effect of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) using

Indexed as

Cell- and tissue-based therapyMesenchymal stem cellsPremature rupture of fetal membranesRegenerative medicineWound healing

Identifiers

PMID41807133
PMCPMC13218840

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.